Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Indian pharma firm Strides Arcolab's subsidiary Onco Therapies has obtained the US Food and Drug Administration (FDA) approval for its oncology product Gemcitabine for Injection USP.
Subscribe to our email newsletter
The approval has been granted for 200mg, 1gm and 2gm dosage strengths.
Gemcitabine for Injection USP, which is a nucleoside metabolite inhibitor that exhibits antitumor activity, is the generic version of the chemotherapy drug Gemzar.
Following the approval, Pfizer is now set to launch the drug in the US market soon, as a part of a licensing deal which was signed between the companies in January 2010.